Tiểu đường loại 2 và nguy cơ suy giảm nhận thức và chứng mất trí nhớ

World Health Organization: Report of the Expert Committee on Diabetes. Geneva, Switzerland; 1980. Report No.: 646. Resnick HE, Harris MI, Brock DB, Harris TB: American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000, 23:176–180. Narayan KM, Gregg EW, Fagot-Campagna A, et al.: Diabetes: a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000, 50(Suppl 2):77–84. Zimmet P: The burden of type 2 diabetes: Are we doing enough? Diabetes Metab 2003, 29:6S9–18. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998, 21:518–524. Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001, 15:169–173. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB: Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000, 24:855–872. Zhao W, Chen H, Xu H, et al.: Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999, 74:34893–34902. Gispen WH, Biessels GJ: Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000, 23:542–549. Zhao WQ, Alkon DL: Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001, 177:125–134. Zhao WQ, Chen H, Quon MJ, Alkon DL: Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004, 490:71–81. Frolich L, Blum-Degen D, Bernstein HG, et al.: Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 1998, 105:423–438. Hoyer S: Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998, 105:415–422. Edland SD: Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease. J Mol Neurosci 2004, 23:213–217. Farris W, Mansourian S, Chang Y, et al.: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003, 100:4162–4167. Farris W, Leissring MA, Hemming ML, et al.: Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 2005, 44:6513–6525. Blomqvist ME, Chalmers K, Andreasen N, et al.: Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer’s disease brain. Neurobiol Aging 2005, 26:795–802. Vanhanen M, Soininen H: Glucose intolerance, cognitive impairment and Alzheimer’s disease. Curr Opin Neurol 1998, 11:673–677. Watson GS, Peskind ER, Asthana S, et al.: Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60:1899–1903. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs 2003, 17:27–45. Craft S, Peskind E, Schwartz MW, et al.: Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164–168. Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3:169–178. Ott A, Stolk RP, Hofman A, et al.: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392–1397. Ott A, Stolk RP, van Harskamp F, et al.: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937–1942. Munch G, Schinzel R, Loske C, et al.: Alzheimer’s disease: synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998, 105:439–461. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223–234. Brownlee M: Negative consequences of glycation. Metabolism 2000, 49(2 Suppl 1):9–13. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001, 44:129–146. Heitner J, Dickson D: Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997, 49:1306–1311. Peila R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002, 51:1256–1562. Schmidt R, Launer LJ, Nilsson LG, et al.: Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004, 53:687–692. Biessels GJ, Kappelle AC, Bravenboer B, et al.: Cerebral function in diabetes mellitus. Diabetologia 1994, 37:643–650. Kamal A, Biessels GJ, Urban IJ, Gispen WH: Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression. Neuroscience 1999, 90:737–745. Magarinos AM, McEwen BS: Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci U S A 2000, 97:11056–11061. Li ZG, Zhang W, Grunberger G, Sima AA: Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 2002, 946:221–231. Whitmer RA, Sidney S, Selby J, et al.: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277–281. Bruce DG, Harrington N, Davis WA, Davis TM: Dementia and its associations in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001, 53:165–172. Curb JD, Rodriguez BL, Abbott RD, et al.: Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 1999, 52:971–975. Leibson CL, Rocca WA, Hanson VA, et al.: The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997, 826:422–427. Luchsinger JA, Tang MX, Stern Y, et al.: Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001, 154:635–641. Macknight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002, 14:77–83. Curb JD, Rodriguez BL, Abbott RD, et al.: Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 1999, 52:971–975. Hassing LB, Johansson B, Nilsson SE, et al.: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 2002, 14:239–248. Ott A, Stolk RP, Hofman A, et al.: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996, 39:1392–1397. Brayne C, Gill C, Huppert FA, et al.: Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998, 9:175–180. Haan MN, Shemanski L, Jagust WJ, et al.: The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999, 282:40–46. Xu WL, Qiu CX, Wahlin A, et al.: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63:1181–1186. Nielson KA, Nolan JH, Berchtold NC, et al.: Apolipoprotein-E genotyping of diabetic dementia patients: Is diabetes rare in Alzheimer’s disease? J Am Geriatr Soc 1996, 44:897–904. Moroney JT, Tang MX, Berglund L, et al.: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999, 282:254–260. Yanagisawa K: Cholesterol and pathological processes in Alzheimer’s disease. J Neurosci Res 2002, 70:361–366. Hofman A, Ott A, Breteler MM, et al.: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997, 349:151–154. Frishman WH: Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis 2002, 4:380–386. in’t Veld BA, Ruitenberg A, Hofman A, et al.: Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001, 22:407–412. Skoog I, Lernfelt B, Landahl S, et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141–1145. Tzourio C, Anderson C, Chapman N, et al.: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069–1075. Elias PK, Elias MF, D’Agostino RB, et al.: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997, 20:1388–1395. Hachinski V, Munoz DG: Cerebrovascular pathology in Alzheimer’s disease: cause, effect or epiphenomenon? Ann N Y Acad Sci 1997, 826:1–6. Breteler MM, Claus JJ, van Duijn CM, et al.: Epidemiology of Alzheimer’s disease. Epidemiol Rev 1992, 14:59–82. de la Torre JC, Mussivand T: Can disturbed brain microcirculation cause Alzheimer’s disease? Neurol Res 1993, 15:146–153. Wong TY, Klein R, Sharrett AR, et al.: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 2002, 33:1487–1492. Merchant C, Tang MX, Albert S, et al.: The influence of smoking on the risk of Alzheimer’s disease. Neurology 1999, 52:1408–1412. Tyas SL, White LR, Petrovitch H, et al.: Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003, 24:589–596. Mooradian AD: Central nervous system complications of diabetes mellitus: a perspective from the blood-brain barrier. Brain Res Brain Res Rev 1997, 23:210–218. Hachinski V, Munoz D: Vascular factors in cognitive impairment: Where are we now? Ann N Y Acad Sci 2000, 903:1–5. Miyakawa T, Uehara Y, Desaki J, et al.: Morphological changes of microvessels in the brain with Alzheimer’s disease. Jpn J Psychiatry Neurol 1988, 42:819–824. Kalaria RN: The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992, 4:226–260. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 2001, 64:575–611. Moody DM, Brown WR, Challa VR, et al.: Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci 1997, 826:103–116. Kalmijn S, Feskens EJ, Launer LJ, et al.: Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995, 38:1096–1102. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996, 27:2230–2235. Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997, 20:438–445. Stewart R, Liolitsa D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999, 16:93–112. Yaffe K GE: Diabetes Mellitus and Cognition. In Harrison’s Principles of Internal Medicine. Edited by Braunwald E, Fauci AS, Isselbacher KJ, et al.: New York: McGraw-Hill; 2001. Gregg EW, Yaffe K, Cauley JA, et al.: Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000, 160:174–180. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K: Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004, 164:1327–1333. Elias PK, Elias MF, D’Agostino RB, et al.: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997, 20:1388–1395. Wu JH, Haan MN, Liang J, et al.: Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 2003, 56:686–693. Hassing LB, Grant MD, Hofer SM, et al.: Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004, 10:599–607. Arvanitakis Z, Wilson RS, Bienias JL, et al.: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61:661–666. Yaffe K, Blackwell T, Kanaya AM, et al.: Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63:658–663. Wu JH, Haan MN, Liang J, et al.: Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a populationbased cohort study. Ann Epidemiol 2003, 13:369–376. Logroscino G, Kang JH, Grodstein F: Prospective study of type 2 diabetes and cognitive decline in women aged 70–81 years. BMJ 2004, 328:5480. Gavin JR: New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1998, 1:1–12. Newcomer JW, Craft S, Hershey T, et al.: Glucocorticoidinduced impairment in declarative memory performance in adult humans. J Neurosci 1994, 14:2047–2053. Messier C, Gagnon M, Knott V: Effect of glucose and peripheral glucose regulation on memory in the elderly. Neurobiol Aging 1997, 18:297–304. Messier C, Desrochers A, Gagnon M: Effect of glucose, glucose regulation, and word imagery value on human memory. Behav Neurosci 1999, 113:431–438. Messier C, Gagnon M: Glucose regulation and brain aging. J Nutr Health Aging 2000, 4:208–213. Worrall GJ, Chaulk PC, Moulton N: Cognitive function and glycosylated hemoglobin in older patients with type II diabetes. J Diabetes Complications 1996, 10:320–324. Naor M, Steingruber HJ, Westhoff K, et al.: Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complications 1997, 11:40–46. Testa MA, Simonson DC: Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998, 280:1490–1496. Gradman TJ, Laws A, Thompson LW, Reaven GM: Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993, 41:1305–1312. Meneilly GS, Cheung E, Tessier D, et al.: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993, 48:117–121. Yaffe K, Whitmer RA, Krueger K, et al.: Glycosylated hemoglobin level and development of cognitive impairment or dementia in older women. J Nutr Health Aging 2006, 4:293–295. Enzinger C, Fazekas F, Matthews PM, et al.: Risk factors for progression of brain atrophy in aging: six-year followup of normal subjects. Neurology 2005, 64:1704–1711. Kalmijn S, Feskens EJ, Launer LJ, et al.: Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995, 38:1096–1102. Kuusisto J, Koivisto K, Mykkanen L, et al.: Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993, 22:771–779. Kern W, Peters A, Fruehwald-Schultes B, et al.: Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001, 74:270–280. Craft S, Asthana S, Newcomer JW, et al.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999, 56:1135–1140. Biessels GJ, Kamal A, Ramakers GM, et al.: Place learning and hippocampal synaptic plasticity in streptozotocininduced diabetic rats. Diabetes 1996, 45:1259–1266. Lannert H, Hoyer S: Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998, 112:1199–1208. Biessels GJ, Kamal A, Urban IJ, et al.: Water maze learning and hippocampal synaptic plasticity in streptozotocindiabetic rats: effects of insulin treatment. Brain Res 1998, 800:125–135. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131–1137. Barzilay JI, Abraham L, Heckbert SR, et al.: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384–2389. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334. Festa A, D’Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47. Schmidt R, Schmidt H, Curb JD, et al.: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168–174. Campbell IL, Abraham CR, Masliah E, et al.: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993, 90:10061–10065. Weaver JD, Huang MH, Albert M, et al.: Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59:371–378. Yaffe K, Lindquist K, Penninx BW, et al.: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76–80. Yaffe K, Kanaya A, Lindquist K, et al.: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237–2242.